Results 261 to 270 of about 98,309 (302)
Some of the next articles are maybe not open access.
Veterinary Immunology and Immunopathology, 2005
The human CD20 antigen, a 35kDa cell surface nonglycosylated hydrophobic phoshpoprotein is expressed consistently on almost all human B-cells, and its monoclonal antibody is used for the therapy on human B-cell lymphoma. In the present study, canine CD20 gene was cloned and sequenced, and the expression of CD20 mRNA was investigated in canine ...
Rui, Kano +7 more
openaire +2 more sources
The human CD20 antigen, a 35kDa cell surface nonglycosylated hydrophobic phoshpoprotein is expressed consistently on almost all human B-cells, and its monoclonal antibody is used for the therapy on human B-cell lymphoma. In the present study, canine CD20 gene was cloned and sequenced, and the expression of CD20 mRNA was investigated in canine ...
Rui, Kano +7 more
openaire +2 more sources
Glofitamab CD20-TCB bispecific antibody
Leukemia & Lymphoma, 2021Bispecific T-cell recruiting antibodies are emerging as a potent immunotherapeutic class in the treatment of B-cell malignancies and act by simultaneously targeting antigens on T-cells and malignant cells to effect tumor cell death. Glofitamab is a novel full-length IgG-like CD20-CD3 bispecific with a unique 2:1 configuration that provides an extended ...
Adrian, Minson, Michael, Dickinson
openaire +2 more sources
Inhibitory FcγRIIb and CD20 internalization
Blood, 2014In this issue of Blood, Vaughan et al demonstrate that certain antibodies that are used therapeutically in lymphoma treatment (e.g., rituximab) undergo Fcg receptor IIb (FcgRIIb)–mediated internalization from the B-cell surface in a manner that is independent of activation of FcgRIIb with important implications for the design of antibody-based ...
openaire +2 more sources
P138 Modulation of CD20 expression on B cells by anti-CD20 antibodies
Human Immunology, 2016Abstract The purpose of this communication is to describe a case that illustrates the interference of in vivo anti-CD20 treatment on B cell crossmatch (B-XM) results. A first kidney transplant candidate, female, white, 31 years-old, with systemic lupus erythematosus, without previous pregnancies, with one blood transfusion more than 15 years ago ...
Elaine C. Bellintani +6 more
openaire +1 more source
Statins Impair Antitumor Effects of CD20 mAb by Inducing Conformational Changes of CD20.
Blood, 2007Abstract A number of monoclonal antibodies (mAb) are presently in development or approved for CD20-directed immunotherapy. Ofatumumab, a human IgG1 anti-CD20 mAb, is currently being evaluated in phase III clinical trials for B-CLL and FL, and in phase II clinical trials for rheumatoid arthritis (RA).
Paul W.H.I. Parren +22 more
openaire +1 more source
Info Onkologie, 2016
Follikulare Lymphome (FL) werden meist im fortgeschrittenen Stadium entdeckt, sodass eine palliative Therapie gefragt ist. Bei vorbehandelten Patienten mit Progress steht nun mit Obinutuzumab plus Bendamustin eine wirksame Alternative zur Verfugung.
openaire +1 more source
Follikulare Lymphome (FL) werden meist im fortgeschrittenen Stadium entdeckt, sodass eine palliative Therapie gefragt ist. Bei vorbehandelten Patienten mit Progress steht nun mit Obinutuzumab plus Bendamustin eine wirksame Alternative zur Verfugung.
openaire +1 more source
CD20 antibodies: doing the time warp
Blood, 2011With the success of the anti-CD20 mAb rituximab in treating B-cell disorders from lymphoma through rheumatoid arthritis, anti-CD20 mAbs are now big business with as many as 16 biosimilars in clinical development. 1 Understanding what makes CD20 such an ideal target and how to select new anti-CD20 mAbs is the subject of intense research.
openaire +2 more sources
CD20 as a gatekeeper of the resting state of human B cells
Proceedings of the National Academy of Sciences of the United States of America, 2021Kathrin Klasener +2 more
exaly
International MS journal, 2008
Immune modulators, such as interferon beta and glatiramer acetate, have focused on T-cells as the primary therapeutic target, although both drugs affect other cell types as well. There has been a renewed interest in the potential roles of both antibody-dependent and antibody-independent B-cell responses in multiple sclerosis (MS) and its animal model ...
openaire +1 more source
Immune modulators, such as interferon beta and glatiramer acetate, have focused on T-cells as the primary therapeutic target, although both drugs affect other cell types as well. There has been a renewed interest in the potential roles of both antibody-dependent and antibody-independent B-cell responses in multiple sclerosis (MS) and its animal model ...
openaire +1 more source